Skip to main content
Log in

Was the thrombotic risk of rofecoxib predictible from the French Pharmacovigilance Database before 30 September 2004?

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objectives

Rofecoxib was withdrawn from the market on 30 September 2004 following the results of a randomized controlled trial. Following this sudden decision, several controversies occurred in the literature to determine whether this adverse drug reaction (ADR) could have been detected earlier. The aim of this study was to investigate whether this kind of signal could have been seen using the French Pharmacovigilance Database before this date of rofecoxib withdrawal.

Methods

Using cases registered in the French Pharmacovigilance Database from May 2000 to December 2006, we applied the case–noncase method to “serious” thrombotic ADRs reported with oral formulations of rofecoxib or celecoxib in patients older than 15 years. Cases were all notifications of thrombotic ADRs [World Health Organization Adverse Reaction Terminology (WHO-ART) codes 1300] occurred under coxib (rofecoxib, celecoxib) and noncases all other reports registered in the database (whatever the drug). We calculated a cumulative odds ratio (OR) from 20 May 2000 to 31 December 2006, with a special interest for the period before the 30 September 2004.

Results

Among the 50,087 “serious” ADRs registered in the database during this period, 1,127 were thrombotic ones. Rofecoxib exposure was significantly associated with high values of odds ratio (OR) [4.2 (95% CI 1.97–8.61)] for thrombotic ADRs as early as the end of 2001. The values of ADR reporting ORs remained high (3.0–3.5) until 2006. For celecoxib, a significant trend occurred only from September 2004.

Conclusion

Despite the compulsory limits of the case/noncase methodology, this study found an association between rofecoxib exposure and the occurrence of “serious” thrombotic ADRs as early as the end of the first year of rofecoxib marketing in France. The association between celecoxib and the occurrence of such ADRs appears less clear. Our work also shows the potential use of careful analysis of pharmacovigilance databases (investigating, for example, cumulative values of risk) in the early identification of new ADRs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307–314

    Article  PubMed  CAS  Google Scholar 

  2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528

    Article  PubMed  CAS  Google Scholar 

  3. Silverstein FE, Faich G Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247–1255

    Article  PubMed  CAS  Google Scholar 

  4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102

    Article  PubMed  CAS  Google Scholar 

  5. Clark DWJ, Laton D, Shakir AW (2004) Do some inhibitors of COX-2 increase the risk of thromboembolic events ? Drug Saf 27:427–456

    Article  PubMed  CAS  Google Scholar 

  6. Montastruc JL, Lapeyre-Mestre M, Gony M, Lugardon S, Bagheri H (2004) Coxibs, which real therapeutic advance? Recent pharmacoepidemiological data. Therapie 59:201–205

    Article  PubMed  Google Scholar 

  7. Arellano FM (2005) The withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf 14:213–217

    Article  PubMed  Google Scholar 

  8. Jüni P, Reichenbach S, Egger M (2005) COX 2 inhibitors, traditional NSAIDs and the heart. Br Med J 330:1342–1343

    Article  Google Scholar 

  9. Nissen SE (2006) Adverse cardiovascular effects of rofecoxib. N Engl J Med 355:203–204

    Article  PubMed  CAS  Google Scholar 

  10. Graham D, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and bnon-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475–481

    PubMed  CAS  Google Scholar 

  11. Strand V (2007) Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 370:2138–2151

    Article  PubMed  CAS  Google Scholar 

  12. Montastruc JL, Sommet A, Lacroix I, Olivier P, Durrieu G, Damase-Michel C, Lapeyre-Mestre M, Bagheri H (2006) Pharmacovigilance for evaluating adverse drug reactions: value, organization and methods. Joint Bone Spine 73:629–632

    Article  PubMed  Google Scholar 

  13. Stricker BH, Tijssen JG (1992) Serum sickness-like reactions to cefaclor. J Clin Epidemiol 45:1177–1184

    Article  PubMed  CAS  Google Scholar 

  14. Egberts AC, Meyboon RH, De Koning FH, Bakker A, Leufkens HG (1997) Nonpuerpueral lactation associated with antidepressant drug use. Br J Clin Pharmacol 44:277–281

    Article  PubMed  CAS  Google Scholar 

  15. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Begaud B (1998) Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/noncase study in the French pharmacovigilance system database. Br J Clin Pharmacol 44:513–518

    Article  Google Scholar 

  16. Egberts AC, Meyboon RH, Van Puijenbroek EP (2002) Use of measures of disproportionality in pharmacovigilance: three dutch examples. Drug Saf 25:453–458

    Article  PubMed  Google Scholar 

  17. Lugardon S, Lapeyre-Mestre M, Montastruc JL, The French Network of Regional Pharmacovigilance Centres (2004) Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/noncase study from the French Pharmacovigilance Database. Eur J Clin Pharmacol 60:673–677

    Article  PubMed  CAS  Google Scholar 

  18. WHO (1992) International monitoring of adverse reactions to drugs: adverse reaction terminology. WHO collaborating Centre for International Drug Monitoring, Uppsala

  19. Begaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugsActualization of the method used in France. Therapie 40:111–118

    PubMed  CAS  Google Scholar 

  20. Van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW (2002) On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of underreporting on odds ratio. Stat Med 21:2027–2044

    Article  PubMed  Google Scholar 

  21. Wilson AM, Thabane L, Holbrook A (2004) Application of data mining data in pharmacovigilance. Br J Clin Pharmacol 57:127–134

    Article  PubMed  Google Scholar 

  22. Shakir SAW (2007) Thoughs on signal detection in Pharmacovigilance. Drug Saf 30:603–606

    Article  PubMed  Google Scholar 

  23. Hand DJ (2007) Principles of data mining. Drug Saf 30:621–622

    Article  PubMed  Google Scholar 

  24. Topol EJ (2004) Failing the public health – Rofecoxib, Merck, and the FDA. New Engl J Med 351:1707–1709

    Article  PubMed  CAS  Google Scholar 

  25. Mukherjee D, Nissen SE, Topol EL (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954–957

    Article  PubMed  CAS  Google Scholar 

  26. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029

    Article  PubMed  CAS  Google Scholar 

  27. Prescrire Rédaction (2002) Effets indésirables cardiovasculaires des coxibs. Rev Prescr 22:596–597

    Google Scholar 

  28. Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arrelano FM (2001) A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre Safety Database. Clin Ther 23:1478–1491

    Article  PubMed  CAS  Google Scholar 

  29. Layton D, Hughes K, Harris S, Shakir SAW (2003) Comparison of the incidence rates of thromboembolic events reported in patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 42:1342–1353

    Article  PubMed  CAS  Google Scholar 

  30. Layton D, Heeley E, Hughes K, Shakir SAW (2003) Comparison of the incidence rates of thromboembolic events reported in patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 42:1354–1364

    Article  PubMed  CAS  Google Scholar 

  31. Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA (2005) A comparison of reported gastrointestinal and thromboembolic events reported between rofecoxib and celecoxib using observational data. Drug Saf 28:803–816

    Article  PubMed  CAS  Google Scholar 

  32. Vu D, Murty M, McMorran M (2002) Selective COX-2 inhibitors: suspected cardiovascular/cerebrovascular adverse drug reactions. Can Adv Reactions News 2:1–3

    Google Scholar 

  33. Warmer TD, Mitchell JA (2008) COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371:270–273

    Article  CAS  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to J. L. Montastruc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sommet, A., Grolleau, S., Bagheri, H. et al. Was the thrombotic risk of rofecoxib predictible from the French Pharmacovigilance Database before 30 September 2004?. Eur J Clin Pharmacol 64, 829–834 (2008). https://doi.org/10.1007/s00228-008-0497-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-008-0497-3

Keywords

Navigation